Hoth Therapeutics Announces Groundbreaking Positive Results: Hoth's HT-VA GDNF Surpasses Semaglutide in Weight Loss, Glucose Control, and Liver Health in Obesity Model
Rhea-AI Summary
Hoth Therapeutics (NASDAQ: HOTH) reported preclinical VA-backed results showing its HT-VA GDNF outperformed semaglutide in a 12-week CF-1 mouse obesity model. Key findings: female weight attenuation 10–15%, fasting glucose normalized, and liver weight reduced 20–30%. Hoth targets IND-enabling studies toward clinical trials in 2027.
Further analyses (liver pathology, lipids, gene/protein expression) are planned to clarify mechanisms.
Positive
- Female weight attenuation of 10–15%
- Fasting glucose fully normalized in treated mice
- Liver weight reduction of 20–30%
- Program advancing toward IND-enabling studies targeting 2027 trials
Negative
- Results are from a preclinical 12-week mouse model, not human data
- Efficacy primarily highlighted in female mice, with less clarity on males
- Further analyses required (pathology, lipids, gene/protein data) before clinical translation
News Market Reaction – HOTH
In the Feb 10 session, HOTH gained 10.68%, reflecting a significant positive market reaction. Argus tracked a peak move of +12.6% during that session. Argus tracked a trough of -14.0% from its starting point during tracking. Our momentum scanner triggered 12 alerts that day, indicating notable trading interest and price volatility. Trading volume was elevated at 2.9x the daily average, suggesting notable buying interest.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Feb 05 | Crypto exposure clarification | Neutral | -4.0% | Company addressed rumors, stating it holds no cryptocurrency assets. |
| Jan 22 | HT-001 interim results | Positive | +0.0% | Positive HT-001 PK cohort data with strong response and tolerability. |
| Jan 21 | HT-KIT China patent | Positive | -1.9% | China patent granted for HT-KIT oncology program, strengthening IP estate. |
| Jan 15 | HT-001 FIH trial setup | Positive | +3.4% | IRB approvals for Phase 2a HT-001 trial and disclosure of cash position. |
| Jan 15 | EU regulatory progress | Positive | +3.4% | Positive EU CTIS Part I conclusion enabling multi-country HT-001 trial sites. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent fundamentally positive announcements have not consistently produced positive price moves, with several clinically and strategically favorable updates met by flat or negative reactions.
Over the past few weeks, Hoth has reported several pipeline and corporate milestones. On Jan 15, 2026, the company advanced HT-001 with EU regulatory clearance and IRB approvals and saw a 3.35% price gain. A key HT-KIT patent in China on Jan 21, 2026 and strong HT-001 clinical response data on Jan 22, 2026 were followed by flat to slightly negative moves. A Feb 5, 2026 clarification about lacking crypto exposure led to a 4.01% decline. Against this backdrop, today’s positive GDNF obesity data adds another clinically oriented catalyst to an already active pipeline narrative.
Key Terms
glial cell-derived neurotrophic factor medical
gdnf medical
metabolic-associated steatotic liver disease medical
masld medical
glp-1 agonists medical
ind-enabling studies regulatory
orphan drug designation regulatory
egfr inhibitors medical
AI-generated analysis. How Rhea-AI works. Not financial advice.
In a head-to-head preclinical comparison, HT-VA co-developed with the United States Veterans Administration GDNF demonstrated superior efficacy compared with semaglutide (the active ingredient in Wegovy®️ and Ozempic®️) across key metrics, including weight stabilization, glucose tolerance, liver weight reduction, and adipose tissue control—particularly in female models
This breakthrough positions GDNF as a potential gamechanger in the
Key Study Highlights:
- Superior Weight Management: In female mice on a high-fat Western diet, GDNF attenuated weight gain by 10
-15% , leading to a plateau in the final weeks of treatment—unlike semaglutide, which showed no significant impact. Researchers noted that higher doses or longer durations could amplify GDNF's effects, suggesting even greater potential for sustained weight loss. - Enhanced Glucose Metabolism: GDNF fully normalized fasting glucose and improved overall response to glucose challenges, outperforming semaglutide in females. Baseline improvements were also seen in males, indicating broad metabolic benefits.
- Liver and Adipose Health: GDNF reduced liver weight by 20
-30% and prevented adipose tissue accumulation in females, surpassing semaglutide's effects. This underscores GDNF's promise in resolving fatty liver disease, a common complication of obesity. - Study Design: Conducted at the Srinivasan Lab with VA support, the 12-week study used CF-1 mice to model human obesity. GDNF was administered subcutaneously with escalating doses (2-12 µg/mouse), compared to semaglutide (12 ng/g/mouse).
"These results are a monumental step forward for Hoth and the fight against obesity," said Robb Knie, CEO of Hoth Therapeutics. "GDNF not only matched but exceeded semaglutide in critical areas, opening doors to a new era of safer, more effective therapies. As we advance this program, we're excited about its potential to deliver life-changing outcomes for patients and significant value for our shareholders."
The study builds on prior research showing GDNF's protective role against diet-induced obesity. Future analyses will include liver pathology, lipid content, and gene/protein expression to further elucidate mechanisms. Hoth plans to accelerate GDNF toward IND-enabling studies, targeting clinical trials in 2027.
Hoth's GDNF program is part of a robust pipeline, including HT-001 (Phase 2 for cancer-related skin toxicities), HT-KIT (Orphan Drug Designation for mast cell cancers), and HT-ALZ (for Alzheimer's).
About Hoth Therapeutics, Inc.
Hoth Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative, impactful, and ground-breaking treatments with a goal to improve patient quality of life. We are a catalyst in early-stage pharmaceutical research and development, elevating drugs from the bench to pre-clinical and clinical testing. Utilizing a patient-centric approach, we collaborate and partner with a team of scientists, clinicians, and key opinion leaders to seek out and investigate therapeutics that hold immense potential to create breakthroughs and diversify treatment options. To learn more, please visit https://ir.hoththerapeutics.com/.
Forward-Looking Statement
This press release includes forward-looking statements based upon Hoth's current expectations, which may constitute forward-looking statements for the purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995 and other federal securities laws, and are subject to substantial risks, uncertainties, and assumptions. These statements concern Hoth's business strategies; the timing of regulatory submissions; the ability to obtain and maintain regulatory approval of existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain; the timing and costs of clinical trials, and the timing and costs of other expenses; market acceptance of our products; the ultimate impact of the current coronavirus pandemic, or any other health epidemic, on our business, our clinical trials, our research programs, healthcare systems, or the global economy as a whole; our intellectual property; our reliance on third-party organizations; our competitive position; our industry environment; our anticipated financial and operating results, including anticipated sources of revenues; our assumptions regarding the size of the available market, benefits of our products, product pricing, and timing of product launches; management's expectation with respect to future acquisitions; statements regarding our goals, intentions, plans, and expectations, including the introduction of new products and markets; and our cash needs and financing plans. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. You should not place reliance on these forward-looking statements, which include words such as "could," "believe," "anticipate," "intend," "estimate," "expect," "may," "continue," "predict," "potential," "project" or similar terms, variations of such terms, or the negative of those terms. Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee such outcomes. Hoth may not realize its expectations, and its beliefs may not prove correct. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including, without limitation, market conditions and the factors described in the section titled "Risk Factors" in Hoth's most recent Annual Report on Form 10-K and Hoth's other filings made with the U. S. Securities and Exchange Commission. All such statements speak only as of the date made. Consequently, forward-looking statements should be regarded solely as Hoth's current plans, estimates, and beliefs. Investors should not place undue reliance on forward-looking statements. Hoth cannot guarantee future results, events, levels of activity, performance, or achievements. Hoth does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events, or circumstances or to reflect the occurrences of unanticipated events, except as may be required by applicable law.
Investor Contact:
LR Advisors LLC
Email: investorrelations@hoththerapeutics.com
www.hoththerapeutics.com
Phone: (678) 570-6791
View original content to download multimedia:https://www.prnewswire.com/news-releases/hoth-therapeutics-announces-groundbreaking-positive-results-hoths-ht-va-gdnf-surpasses-semaglutide-in-weight-loss-glucose-control-and-liver-health-in-obesity-model-302682954.html
SOURCE Hoth Therapeutics, Inc.